The Menopause Institute of Australia
(This site finally disappeared in 2009. The ACCC media releases have been kept here as a warning to other potential crooks.)
The web site of The Menopause Institute of Australia was looking a bit empty on August 13, 2006. Perhaps this media release from the Australian Competition and Consumer Commission explains why.
ACCC institutes against Menopause Institute of Australia, Managing Director alleging misleading and deceptive health claims
The Australian Competition and Consumer Commission has instituted legal proceedings against Menopause Institute of Australia Pty Ltd and its managing director, Dr Gary Aaron, alleging misleading and deceptive conduct in the advertising and promotion of its Natural Hormone Replacement Therapy Program for the treatment of menopause.
The ACCC has alleged in the Federal Court that Menopause Institute breached section 52 of the Trade Practices Act 1974 by making misleading and deceptive representations about:
The ACCC alleges that more than 30 representations made by Menopause Institute are misleading or deceptive, including that NHRT:
The ACCC has also alleged that Dr Aaron, as managing director of Menopause Institute, authorised the making of representations by Menopause Institute that contravene section 52 of the Act.
The representations of concern to the ACCC were made in a variety of media, including a series of newspaper advertisements published in the Sun Herald and Sunday Telegraph; a television commercial aired on metropolitan and regional television networks across Australia; a series of radio advertisements aired on commercial radio stations; in brochures and other promotional material provided to prospective and current patients of Menopause Institute, and on the Menopause Institute's website (www.menopauseinstitute.com.au).
The ACCC is seeking court orders including:
A directions hearing for this matter is listed before Justice Branson for 31 August 2006 in the Federal Court, Sydney.
Release # MR 173/06
Issued: 4th August 2006
Menopause Institute admits deceiving its patients about menopause treatments
The Menopause Institute of Australia has admitted misleading and deceiving its patients and potential customers about the safety and effectiveness of its Natural Hormone Replacement Therapy Program for the treatment of menopause, as part of a court settlement.
The Menopause Institute and its managing director at the time of the relevant conduct, Dr Gary Aaron, have also consented to a range of other remedies as part of the settlement.
The ACCC instituted legal proceedings in the Federal Court in July this year alleging that the Menopause Institute had breached section 52 of the Trade Practices Act 1974 by making misleading and deceptive representations about:
The ACCC alleged that numerous representations made by Menopause Institute were misleading or deceptive, including that NHRT:
The ACCC has also taken proceedings against Dr Gary Aaron for his involvement in the contraventions.
The Menopause Institute has admitted, for the purposes of the proceedings, that approximately 75 separate medical claims made by the company in a variety of media were misleading and deceptive. These misrepresentations appeared in the following media:
The Menopause Institute and Dr Aaron also consented to wide ranging injunctions to prevent a repetition of these representations for a period of three years.
The ACCC also required the Menopause Institute to undertake corrective measures to alert its former and current patients about the potentially misleading representations which the Menopause Institute made about the safety and effectiveness of its menopause treatments, being to:
The Menopause Institute was also ordered to pay the ACCC's costs of $50,000.
"The ACCC pursued this matter because of its serious concerns about the representations being made by the Menopause Institute concerning the safety and effectiveness of its menopause treatments", ACCC Chairman, Mr Graeme Samuel, said today. "In the ACCC's view the claims being made by the Menopause Institute were blatantly misleading and deceptive.
"Furthermore, the ACCC was concerned that a number of the Menopause Institute's misrepresentations about the safety of their treatments, including the claimed absence of side-effects, may have exposed their patients to serious risks.
"Companies which seek to make claims about the efficacy of their treatments must ensure that they have a reasonable basis for making such claims. The ACCC will take appropriate action, including legal action, against any company which make exaggerated and unsupportable medical claims.
"In the present case the ACCC was also determined to ensure that the Menopause Institute take all steps necessary to adequately warn their patients about the health risks. Without such corrective measures these patients may have remained unaware of the serious medical risks of Menopause Institute's NHRT treatments".
Release # MR 316/06
Issued: 20th December 2006